insights into the results and implications of the commands & imerge studies in lr-mds
Published 1 year ago • 66 plays • Length 2:33Download video MP4
Download video MP3
Similar videos
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:44
imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
19:00
case study: sequencing therapy in es-sclc in special patient populations
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
1:30
insights into the manifest-2 study
-
1:41
using cytogenetics to improve the diagnosis and prognosis of mds & to predict response to treatment
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
3:21
an insight into the standard of care in hr-mds and future outlooks
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
1:08
the impact of extramedullary multiple myeloma on outcomes with ide-cel
-
2:07
ipps-m: incorporating genomic data into the ipps criteria for mds
-
4:48
an insight into the management of cytopenias in mf
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:03
an insight into the sequencing of immunotherapies in adults with all
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?